LAG3 and glioblastoma: Therefore, we investigated the possible role of our Immune-related lncRNAs signature, radiomics signature in the ICB therapy of GBM by evaluating the relationships of the eight well known targets of immune checkpoint inhibitors (including PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM1, IDO1) to the immune-related lncRNAs signature and radiomics signature (Fig. 5A).